Compare CRNX & HLNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRNX | HLNE |
|---|---|---|
| Founded | 2008 | 1991 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.7B |
| IPO Year | 2018 | 2017 |
| Metric | CRNX | HLNE |
|---|---|---|
| Price | $33.65 | $94.71 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $74.78 | ★ $164.78 |
| AVG Volume (30 Days) | ★ 1.0M | 768.1K |
| Earning Date | 05-07-2026 | 02-03-2026 |
| Dividend Yield | N/A | ★ 2.21% |
| EPS Growth | N/A | ★ 41.64 |
| EPS | N/A | ★ 3.98 |
| Revenue | $1,039,000.00 | ★ $712,963,000.00 |
| Revenue This Year | $722.66 | $9.81 |
| Revenue Next Year | $183.79 | $19.69 |
| P/E Ratio | ★ N/A | $24.49 |
| Revenue Growth | N/A | ★ 28.73 |
| 52 Week Low | $24.10 | $92.77 |
| 52 Week High | $57.99 | $179.19 |
| Indicator | CRNX | HLNE |
|---|---|---|
| Relative Strength Index (RSI) | 29.20 | 33.68 |
| Support Level | $33.23 | $92.77 |
| Resistance Level | $37.23 | $104.22 |
| Average True Range (ATR) | 1.62 | 3.71 |
| MACD | 0.13 | 0.75 |
| Stochastic Oscillator | 8.33 | 15.00 |
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Hamilton Lane Inc is a private markets investment firm globally, providing solutions to institutional and private wealth investors around the world. Dedicated exclusively to private markets investing for more than 30 years, the firm currently employs approximately 750 professionals operating in offices throughout North America, Europe, Asia Pacific, and the Middle East. It has approximately $986 billion in assets under management and supervision, composed of nearly $141 billion in discretionary assets and more than $845 billion in non-discretionary assets. The group specializes in building flexible investment programs that provide clients access to the full spectrum of private markets strategies, sectors, and geographies.